Target-controlled infusion (TCI) has been available as a routine clinical tool for anaesthetists in Australia and New Zealand and many other parts of the world outside the USA 1 since the introduction of the Diprifusor nearly 15 years ago. More recently, the introduction of infusion devices supporting 'open TCI' has allowed TCI to be used for drugs other than propofol and given users a choice of propofol models. This apparent flexibility has produced what Enlund 2 calls "Totally Confused Infusion" -at least in our department! The commonly used propofol models have significant differences 3 ; there are different versions of the so-called Marsh model, the user needs to choose between plasma and effect site targeting and implementation of the same model, and therefore dosing can differ between brands of open TCI pumps.
That there are multiple propofol models reflects the ongoing evolution of modelling tools and of the models themselves and the development of measures of endpoints for calibrating model performance. The ongoing quest for new and improved models also tries to overcome the known deficiencies of existing models, answer questions raised in previous studies and enhance understanding of the disposition of these agents. The paper in this issue of the Journal by Crankshaw et al 4 is part of ongoing efforts to overcome problems with previous models and enhance our understanding. This group had an interest in TCI long before the tools became available to the rest of us 5,6 .
The performance, or accuracy, of models has been measured in a variety of ways. Early reports focused on the size of the difference between calculated and measured levels 7 . Median errors of up to 60% have been reported in clinical studies 8 . Measures of drift, or the change in bias over time, are often calculated 9 . In clinical practice, stability, or the absence of drift, may be as important as the degree of error or of the bias. If there is drift, then the level required to maintain any clinical endpoint will change over time.
No matter how refined and stable models eventually become and how many covariates are included 10 , the models used in TCI systems are based on data from previous patients and not the patient you are about to anaesthetise. It is well known that propofol dose requirements for both induction and maintenance vary enormously, with six-fold differences in induction dose reported 11 . Although genetics seem to provide clues to dose requirements for opioids 12, 13 , at present this does not appear to be the case with propofol 11 . Models are unlikely to ever provide perfect predictions for individuals.
If we cannot reliably use modelled drug levels as the endpoint to control anaesthesia, what else can we use? Can we somehow use observation of the various effects of the drugs we administer as our 'target'?
Many anaesthetists consider their clinical skills the gold standard for determining depth of anaesthesia. There is evidence that using only clinical endpoints frequently produces unnecessarily deep anaesthesia [14] [15] [16] and that inexperienced anaesthetists cannot differentiate between light and deep levels of hypnosis as determined by bispectral index monitoring (BIS) levels 14 . There is increasing data suggesting an association between periods of deep levels of hypnosis and increased long-term morbidity and mortality [17] [18] [19] [20] . Of course, so-called clinical measures actually involve the use of various physiological monitors.
Devices that measure the degree of hypnosis have been available commercially for almost as long as TCI systems. Use of BIS has been shown to reduce the incidence of awareness in high-risk patients 21 and probably wider populations 22 . Like all monitors and clinical skills, these devices are not perfect. Cynics point out that data from these same studies and others 23 , a plethora of individual case reports and letters and, of course, anecdotes, provide examples of awareness when these devices have been used and of apparent paradoxical behaviour. Despite this, overall the use of BIS, and almost certainly State Entropy and other similar technologies, are associated with decreased incidence of awareness, decreased drug consumption, more rapid recovery and decreased postoperative nausea 24 .
Are these small but repeatable improvements in short-term recovery important? Dexter et al 25 have recently suggested that differences in times to extubation of a few minutes do indeed produce a demonstrable economic benefit.
Considering propofol delivery as the input and a value derived from electroencephalogram Anaesth Intensive Care 2010; 38: 421-423 Editorials Individualising target-controlled anaesthesia. Better models or better targets? monitoring as the output implies that anaesthesia is one-dimensional. Glass 26 usefully decomposes the definition of anaesthesia into lack of recall and lack of response to stimulation. Clinically we measure response to stimulation by both sympathetic and motor responses. Monitors that quantify the nociceptive component of anaesthesia, including the 'Composite Variability Index' being developed by Aspect and the 'Surgical Pleth Index' from GE Healthcare (also known as SSI), are under development. This type of device will eventually help guide delivery of opioids, allowing control of a second dimension of anaesthesia.
Modelling of drugs is also becoming multidimensional. Devices that incorporate response surface modelling to predict the combined effect of hypnotics and opioids on both hypnosis and 'analgesia' [27] [28] [29] are available within the GE Navigator and Dräger SmartPilot. Once the various components are validated, the combination of this type of modelling with monitors of both hypnosis and response to noxious stimulus has the potential to allow much better the needs of an individual patient at different stages of a procedure with the actual requirement and opens the way for useful closed-loop delivery systems 30, 31 .
But what are we to do while we wait for these magic devices?
We need to understand the way different infusion pumps and TCI models work, in the same way we should understand the behaviour of different breathing circuits under different conditions. We also need to understand the function and limitations of newer monitors in the same way we acknowledge deficiencies of familiar devices such as end-tidal agent and CO 2 monitors and pulse oximetry.
We should accept that TCI and other delivery models will never be perfect in the same way we recognise that monitors of anaesthetic effect are not perfect. However, taken together, the combination offers the opportunity to better control anaesthesia. Billard 19 has suggested that TCI systems can be used to supplement the qualitative assessment provided by monitors such as BIS. Perhaps the converse is equally true: that monitors such as BIS are useful adjuncts to TCI systems.
The combination of improved models of drug distribution and monitoring of effect has the potential to better match drug delivery to changing needs to produce better outcomes for our patients in both the short-and long-term. Surely these are essential targets for all anaesthetists.
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